semaglutide gastric stasis class action in louisiana legal team glp-1 attorney glp-1 gastric stasis semaglutide gastric stasis class action – louisiana glp-1 gastric stasis class

The three most recent Phase 3 readouts are: TRIUMPH-4 (December 2025) showing 28.7% weight reduction at 68 weeks in obesity with knee osteoarthritis, TRANSCEND-T2D-1 (March 2026) showing A1C reductions up to 2.0% and 16.8% weight loss at 40 weeks in type 2 diabetes, and TRIUMPH-1 (May 2026) showing up to 25.0% weight reduction at 80 weeks in the pivotal obesity trial

These benefits were further supported by the results of the SUMMIT trial, which investigated tirzepatide, a dual GLP-1/glucose-dependent insulinotropic polypeptide receptor agonist, in patients with HFpEF with or without T2D

its about helping your body function more efficiently from the inside out

If youre considering Ozempic for weight management, eligibility is determined by your provider since it is prescribed off-label

Dec 20 2017;13(1):395